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INTRODUCTION 
Survivin has been characterized as a member of the family of inhibitor of 
apoptosis proteins (lAP). It is a 16.5 kD protein made up of 142 amino acids. Survivin is 
expressed in the G2/M phase of the cell cycle. It has been previously sho\vn to be 
expressed in a large number of cancers, and its expression has been associated with the 
aggression of tumors, or with the poor survival of cancer patients. 
OBJECTIVE: To develop a clinically useful assay for the detection of survivin in breast 
cancer by immunohistochemistry. 
IMPACTS OF THE STUDY 
1. Comprehensive training in the production of immunohistochemistry assay system. 
2. The results of this present study gave the information on, which was the better 
oligopeptide from selected oligopeptides to use for antibody production raised 
against survivin or the mixture, and which the better protocol of immunization 
between rapid method and conventional method. 
3. They also gave the preliminary data on survivin expression in breast cancer 
among the Malaysian patients who were registered in University of Science of 
Malaysia Hospital, Kota Bharu General Hospital and Kuala Terengganu General 
Hospital.. 
4. The preliminary information of survivin expression in breast cancer could be used 
for the further study on other types of cancers in the future, in addition to the 
potential for expanding the breast cancer work. 
METHODOLOGY 
Peptide selection and design 
Two sequences of survivin molecule were selected for peptide synthesis were C-
terminal and N-terminal of survivin sequence of human origin. 
Peptide I was 12 amino acid sequence (MGAPTLPPA WQP)~ molecular formula 
C59 H88 N14 015 SI and Peptide II was 21 amino acids sequence 
(KEFEETAKKVRRAIEQLAAMD)~ molecular fonnula CI06 HI79 N31 034 SI. 
Peptide I and Peptide II were purchased from Peptron (Korea), specially purified 1:,rrade 1 
Preparation of antigen for immunization 
Survivin is a stnaii antigen with a molecular weight of 16.5 kD. To increase its 
immunogenicity, selected sequence of amino acids of C-terminal and N-tenninal of 
survivin molecule were conjugated to keyhole limpet homocynine (KLH) using 
glutara1 aldehyde method. Glutaraldehyde (grade I) will crosslink via free amino !,'TOups, 
i.e. the amino tenninal of the peptide and/or the epsilon amino group of lysine. 
Animals 
Animals (New Zealand white rabbits) were purchased from The Animal House, 
School of Medical Sciences, University of Sciences of Malaysia. Healthy female Nev1 
zealand white rabbits aged 3-4 months (body \veight ~ 3 kg) lived in animal house at 
least for 3-5 days for adapting to the new circumstance. Females \vere preferred as they 
often produce a stronger immune response (Clark et al. 2002 ). 
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Polyclonal antibody production 
These preparations based on Hu et al. (2002). Sample A : Peptide 200-300 J.lg 
was emulsified in PBS with same volume of the Freund's complete adjuvant (3-4 mg/ml) 
heat -killed Bacillu .. \· tubercle in lanonin: mineral oil =2:5 [v/v] ) in 1 ml total volume. 
Sample B: Peptide 200-300 J.lg was emulsified in PBS with same volume of the Freund's 
incomplete adjuvant (no Bacillus tubercle) in I ml total volume. 
The conventional method: On the first day, 1.5 ml blood was colJected by 
bleeding rabbits from the marginal vein of the ear for preparing the pre-immunized sera 
as internal negative control. 1.5 ml of blood from the control rabbits (without any 
immunizations) also was taken as external negative control. Afterwards, 1 ml of sample 
A was injected subcutaneously on the right flank of the rabbit. Subcutaneous injections 
was preferred in order to minimize the fonnation of sterile abscesses (Clark et al. 2002). 
This method needed several sample B injections in every 2-4 weeks successively. The 
name of this antibody was SUR12A-CFI. 
The rapid method : Exactly same as the conventional method, except there is an 
additional sample A injection on the 3rd day. On the third day, the injection was repeated 
once to strengthen the first immunization stimulation. On the 28th day, 1 m1 sample B 
\vas injected by the same way. On the 35th day, 0.5 ml blood \Vas collected by the same 
way used before for checking its titer of the antisera .. Then, the antisera was harvested 
from the marginal vein of the ear. The name of this antibody was SUR 12A-RFI. 
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Immunostaining of antisera against survlvin in colon cancer and breast cancer 
sections. 
Briefly, the immunohistochemistry of paraffin-embedden sections from colon 
cancer and breast cancer was done by using ABC method (DAKO). The dilution of 
primary antibody SUR12A-CFI was 1: 1280 (after cheuqerboard done) and latter step 
was according to the manufacturer's direction. Antisera staining was developed by 3'3-
diaminobenzidine (DAKO). Slides were counterstained by Eosin complex and 
Haematoxy1in. 
Evaluation of me results. 
The mean percentage of positive tumor cells was detennined in at least five areas 
at 400-fold magnification and assigned one of the following five categories: 0, <5o/o~ 1, 5-
25%; 2, 25-50%; 3, 50-75%; and 4, >75%. The intensity of survivin immunostaining was 
scored as follows: 1 +, weak; 2+, moderate; and 3+, intense. Because tumors showed 
heterogenous staining, the dominant pattern was used for scoring. 
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RESULTS 
Table 1 Determination of optimal titers for indirect immunoperoxidase method 
(Chequerboard titration for SUR 12A-RFI antibody) 
I I Dilutions of primary antibody I> 
I SUR12A-RF1 
Dilutions of 115 l/20 1180 11320 111280 Negative 
secondary control 
antibody 1/40 +++ +++ +++ +++ +++ 0 
(conjugate) (+++) (+++) (+++) (+++) (++) 0 
1 
1/80 +++ +++ +++ +++ +++ 0 
(+++) (+++) (+++) (++) (++) 0 
1/160 +++ +++ +++ +++ -r-++ 0 
(+++) (+++) (+ +-) (++) ( -i+) 0 
Negative control (primary antibody \vas omitted, and \Vas replaced by 
Bovine serum albumin (BSA) or normal serum or preimmunized serum). 
Intensiy of specific staining is indicated as scale 0 to +++, nonspecific 
backgro\md given in the srune scale in parentheses ( 0 to +++) 
Eg. ( +++) indicates strong specific staining \Vith moderate background 
(+) 
6 
Tahk 2 . Tht! plates or chequcrhoard titration or primary antibody SU I~ 12/\ -R FI 111 
fi xed dilution or secondary antibody( l : l 60). 
Intensit y of specific st<~ining +++ 
Nonspecific b<1ckground ( ++ t- ) 
Magniti c<~tio n );' -100 
!Jilutioll : I 5 (I I ()0) 
Intensi ty of specific staining +++ 
Nonspecific b<1ckground ( +" ) 
M agnification X -100 
/)ilution : I 320 ( I 160) 
Intensity of specific staining +++ 
Nonspecific background ( +++) 
Magnification X-100 
/Jilulioll : I 20 (/ / 160) 
Intensity of specific staining -h -.-
Nonspeci fi c background (+ -'-) 
Magnificat ion );' -100 
/ . 128U (! 160) 
Int ensi ty of specific swining +H 
Nonspecific background ( ++ ) 
:VIagni fication X -1(}0 
/J iluEio11 : I 80 (I I uOJ 
lntcnsil\' of spcctt"tc stallllllg ( 0) 
:-..'onspccilic background ( 0 ) 
Magnilicmion X -100 
t\'t'gnfi\'L' COIIf/'u{ II l(htlllf fJJ'/J/101 ')' .·lh 
<I I' 1101'111<11 m/lhil <llllis,·n<nt 
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Figure 1: The chequerboard titration of primary Ab 
SUR12A-RFI in fixed dilution of secondary Ab 
(1 :40) 
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~ Figure 2 :The cheqeurboard titration of primary Ab 
( SUR12A-RFI in fixed dilution of secondary Ab 
' (1: 80) 
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Figure 3: The chequerboard titration of primary Ab 
SUR12A-RFI in fixed dilution of secondary Ab 
(1 :160) 
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Table 3 Determination of optimal titers for indirect immunoperoxidasc method 
(Chequerboard titration for SUR 12A-CFI) 
Dilutions of primary antibody ~ 
SUR12A-CFI 
Dilutions of 1/5 1/20 1/80 1/320 111280 Negative 
secondary control 
antibody l/40 +++ +++ ++ ++ +++ 0 
(conjugate) (+++) (+++) (+++) (+++) (++) 0 
1180 +++ +++ +++ +++ +++ 0 
(++) (++) (+++) (++) (++) 0 
~, 1/160 +-t--+· -++ ._. i- ~i - ._ _.,. +++ 0 
(+++) ( : ~-+) ( + +) (' ;_) (+) 0 
Negative control (primary antibody was omitted, and was replaced by 
bovine serum albumin (BSA) or normal serum or preimmunized serum). 
Intensiy of specific staining is indicated as scale 0 to +++, nonspecific 
background given in the same scaJe in parentheses ( 0 to +++) 
Eg. { +++) indicates strong specific staining v~ith moderate background 
(+) 
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Table .J : The pl~l tcs nr c hcqcurbl)~Hd titration nr primary anti body Sl iR 12.1\-CFI in 
l't:\ed dilution nr secnndary antibody (I: 160) 
lm ensitv of specific staining 1 1 I 
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Magnification X -!00 
/)i/ulion : J. 5 
t. 
~.· ·~~ 
'-1 ~-~ ~ · ~ 
\. t -b 
I ~ *~: • '"! 
! Intensity of specific staining +++ 
I Non-specific background (-1-t ) 
j 0~gnification X-100 
L11'i~~~~l)-(~ j()l}j 
Intensity of specific staining 1 1 1 
Non-specific background ( +++) 
Magniflcation X -100 
JJilution: 1120 
l nt ensity of specilic staining +++ 
Non-specific background (+ ) 
Magniftcation )( -100 
I I 2SO ( 1: 1 60) 
Inten sity of~peci fic staining 1 1 1 
Non-speci fic background ( ++ ) 
jv1agqiflcation X -100 
})i/u!Jrm: 1 80 J(j() 
Int ensity of specific staining ( 0) 
Non-specilic background ( 0 ) 
Magnilictl tion X -100 
Nexori ve (.'111/fro/ : without Jil'immy 
A h normal ruhhil onlt.wrum 
II 
.0 
~ 
2:' 
Figure 4: The cheqeurboard titration of primary Ab 
SUR12A-CFI in fixed dilution of 
secondary Ab (1 :40) 
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Figure 5: The chequerboard titration of primary Ab 
SUR12A~CFI in fixed d ilution of 
secondary Ab (1 :80) 
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Figure 6: The chequerboard titration of primary Ab 
SUR12A-CFI in fixed dilution of secondary Ab 
(1:160) 
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Table 5 : Immunostai ning of antisera against survivin in the colon cancer tissue. In this 
section, the immunosta in ing was restricted to the cytoplasm of the colon 
cancer ce ll s. 
Prei mmunized antisera 
(Negative control) 
Mnt.mificn tion x400 
Spc~ illc staining (0) 
Nonspecific background 
staining (0) 
Drlut 1ons 1: 1280(_ 1: 160) 
Magnifica tion x400 
Specific stain ing ( 1 1 1 ) 
Nonspecif ic backgrounJ 
sta ining (-t 1) 
Di lut ions I 128(! ( I 160) 
Magnification x400 
Specific staining ( 1 1 1 ) 
Nonspecific background 
staining ( i ) 
Dilut(9ns I: 1280_( 1· 1 60) 
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lmnHlnohistol'hrmil·nl ann lys is of hrrnst l':l llCl'r sel'tions (prl'limitutry results) 
The plates h~IO\Y (1-'igure 7. 1 and Figure 7.2) shO\\'S the posi t iv~ immunnstaining 
or sun mn 1n breast canc~r tissues using SUR 12A-CFI ant ibody with different 
magni !"icatinn. 
l 
Fiourc 7_ 1 
0 
I 
_ , 
... 
·~ .. ..... 
Survi vin staining in breast cancer showing strong ( + 3 ) cytoplasmic and 
nuc lear positivi ty (arrows) in tumor cell s (Magnifica tion x 100) using 
SUR 12A-C FI Ab dilution I: 1280 
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Figure 7.2 Survivin stainin.g.(arrows) in breast cancer ~how~ng strong (+3) cytoplasmic 
and nuclear posJtJvJty 1r1 tumor cell s (Magmficat1 on x 400) using SUR 12A-CFI 
J\b dilution l : 1280 
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DISCUSSION 
Immunohistochemistry (IHC), is a method utilized for localizing specific 
antigens in tissues or cells based on antigen-antibody reaction. According to Taylor et al. 
(2002), IHC is a sensitive detection systems, that is why we have chosen this method to 
detect the survivin protein in the tissues or cells, instead of other methods. Based on this, 
the antibodies SUR12A-CFI and SUR12A-RFI were produced. They were raised against 
selected oligopeptides. These antibodies were further used to construct an 
immunohistochemical assay system for the detection of survivin. Survivin was detected 
successfully in those assay in positive tissues. Moreover, a stringent standardization 
protocol utilizing professional chequerboard assays, were performed 
Determination of optimal titers for indirect immunoperoxidase method 
Chequerboard titration for SUR l2A-CFI and SUR 12A-RFI \vere performed to 
investigate the optimal dilutions for those antibodies for using in IHC to detect survivin 
in colon cancer and breast cancer tissues. This selection of positive controls was based 
on previous findings stating that colon cancer displays a high rate of expression of 
survivin (Sarela et al. 2001 ). Consequently colon cancer was used in this work for the 
initial testing of the assays, and for the standardization in the chequerboard assay, 
performed. 
It \vas found that the optimal dilution for SUR l2A-CFI was 1: 1280 and 1:160 
for the secondary antibody whilst for SUR 12A-RFI was 1: 1280 and secondary antibody 
1: 160_ Even though the optimal dilution for those antibodies were the san1e but the 
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results were based on the contrast of the intensity of specific staining of survivin and the 
intensity of nonspecific background staining .(Refer Table 2 and Table 4 ). As a results, 
SUR 12A-CFI gave more specific positive staining compared to SUR 12A-RFI. This 
intensity was more contrast compared to SUR 12A-CFI (refer Table 5 ). Evidently, 
survivin detected efficiently in breast cancer in the following stages of the work. 
According to Taylor et al. (2002), the optimal dilution for use of an antibody in 
immunohistology is defined as that dilution at which the greatest contrast is achieved 
between the desired (specific) positive staining and any unwanted (nonspecific) 
background staining Based on this definition, in this study, again, it was found that the 
SUR 12A-CFI antibody produced by the conventional method of immunization protocols 
gave a better positive staining of survivin and lesser nonspecific background staining 
compared to the SUR I2A-RFI antibody produced by the rapid method of immunization 
protocols (Table 2 and Table 4) 
Quality control 
Quality control as define by the College of American Pathologist is "the aggregate 
of processes and techniques so derived to detect, reduce and correct deficiencies in 
analytical process". As it pertains to IHC, quality control standards address and define 
each step of the "total IHC test", including tissue procurement~ fixation~ processing, 
sectioning~ staining, and finaJly, the interpretation and reporting of the results (Taylor et 
al. 2002). In this study, based on the definition above, the rules were abided by~ during 
h d t
. 0 stages as well as the testing stages. t e pro uc to , 
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After finishing the chequerboard titration of those antibodies using selected 
colon cancer tissues, we chose to use SUR l2A-CFI antibody to detect survivin protein in 
breast cancer tissues which was the main objective of the study. In this study~ we have 
tested the performance parameters including the sensitivity, specificity, precision, 
accuracy~ and reproducibility of the results. We used multitissues control blocks 
containing known positive (which is known to contain the survivin) which, was selected 
colon cancer tissues and known negative normal which was adjacent normal breast 
tissues (internal controls) and tumor tissues which was breast cancer tissues. 
According to Taylor et al. (2002), the specificity of antibody staining is shown by 
the expected absence of staining in certain cells (there was some cells not stained even 
though other types of cell stained in the same slide) of survivin positive tissues, tissues 
(nonnal breast tissues; absence of staining), and tumors (not all tumor shows survivin 
positive staining) \vith the multitissue control blocks Precision , in contrast , attest to the 
validity of the entire procedure and it shown by the presence of both positive and 
negative elements, as expected on the same control slide (same with there was some cells 
not stained even though other types of cell stained in the same sections of survivin 
positive tissues). A sensitive test is one , that detects a small amount of survivin antigen. 
It was found that a few slides detected a small amount of survivin antigen which the 
percentage of positivity of the cells less than 25°/o. Accuracy is determined by the 
evaluation of nonspecific background staining . A negative reagent control was used 
(substitution of the primary antibody with antibody diluent (butTer plus bovine serunl 
albumin (BSA) carrier protein) or nonnal rabbit serum or preimmunized rabbit serum) 
18 
instead of SUR 12A-CFI. It was found that there was no run-to-run variations in the 
results obtained, which indicated the high reproducibility of the assay systems developed. 
CONCLUSIONS 
The polyclonal antibodies raised against survivin that were produced in the 
present study gave a good detection signal of survivin molecule in immunohistochemical 
assay. 
(THIS IS A PRELIMINARY REPORT FOR PHASE I AND WE ARE WAITING FOR 
THE RELEASE OF T~ USM SHORTERM GRANT PART 2 TO CONTINUE THE 
PHASE II OF THE STUDY. WE WILL GIVE A COMPLETE REPORT AFTER 
FINISHING THE PHASE II OF THE STUDY INCLUDING, HOPEFULLY, THE 
ANTICIPATED PUBLICATION. THANK YOU). 
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